Market Risers: Applied Graphene Materials, AstraZeneca, Avacta Group, Burberry Group

Avacta Group

Shares of Applied Graphene Materials EPIC code: LON:AGM has risen 9.68% or 1.5 points throughout today’s trading session so far. Market buyers have remained optimistic during the session. The high for the period has peaked at 18 while the low for the session was 16.7. The total volume of shares exchanged through this period comes to 36,703 while the average shares exchanged is 78,913. The 52 week high is 37.4 around 21.9 points difference from the previous days close and the 52 week low at 14 which is a variance of 1.5 points. Applied Graphene Materials now has a 20 SMA of 16.38 and now the 50 day SMA of 17.24. The market capitalisation currently stands at £8.40m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for Applied Graphene Materials being recorded at Wednesday, January 15, 2020 at 11:35:19 AM GMT with the stock price trading at 17 GBX.

The stock price for AstraZeneca with EPIC code: LON:AZN has stepped up 1.25% or 95.78 points throughout the session so far. Buyers have remained optimistic throughout the trading session. The periods high has already touched 7794 and hitting a low of 7703.96. Volume total for shares traded during this period was 197,960 with the daily average number around 2,091,668. The 52 week high is 7824 equating to 133 points difference from the previous days close and the 52 week low at 5312 which is a difference of 2379 points. AstraZeneca now has a 20 moving average of 7705.12 and now its 50 day SMA of 7518.61. The market cap now stands at £102,202.43m at the time of this report. All share prices mentioned for this stock are traded in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Wednesday, January 15, 2020 at 11:44:00 AM GMT with the stock price trading at 7786.78 GBX.

The trading price for Avacta Group company symbol: LON:AVCT has increased 9.12% or 1.63 points during today’s session so far. Traders seem confident during the session. The high for the period has peaked at 20.19 dropping as low as 17.48. The total volume of shares traded by this point was 2,479,873 while the daily average number of shares exchanged is 178,963. The stock 52 week high is 49.8 around 31.92 points difference from the previous close and the 52 week low at 15 making a difference of 2.88 points. Avacta Group has a 20 SMA of 17.65 and now a 50 day moving average of 17.78. Market capitalisation for the company is £34.31m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for Avacta Group being recorded at Wednesday, January 15, 2020 at 11:43:41 AM GMT with the stock price trading at 19.51 GBX.

The stock price for Burberry Group EPIC code: LON:BRBY has climbed 1.5% or 34 points throughout today’s trading session so far. Investors are a positive bunch during this period. The high for the period has peaked at 2313 and a low of 2267.72. Volume total for shares traded at this point reached 407,182 with the average number of shares traded daily being 1,435,428. The stock 52 week high is 2362 around 91 points difference from the previous days close and putting the 52 week low at 1678 a difference of some 593 points. Burberry Group now has a 20 simple moving average of 2229.74 and now the 50 day MA at 2152.84. This puts the market cap at £9,381.36m at the time of this report. The currency for this stock is Great British pence.Market cap is measured in GBP. This article was written with the last trade for Burberry Group being recorded at Wednesday, January 15, 2020 at 11:43:57 AM GMT with the stock price trading at 2305 GBX.

Share on:
Find more news, interviews, share price & company profile here for:
AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases.
AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.

Search

Search